# testHP

## Biological Monitoring & Longevity Research Platform

`testHP` is a research-oriented platform for building a **multimodal, longitudinal model of human biological state**. The long-term vision is to monitor the organism at multiple biological levels, detect abnormalities and ageing-related changes, understand how they evolve, and eventually evaluate interventions that preserve or restore biological function.

> **Vision:** treat the human body as a dynamic biological system rather than reducing health to one score or one diagnosis.

The long-term ambition includes research into exceptionally long healthy lifespans, potentially including a 200-year human lifespan. This is a research vision, not a current capability or medical claim.

---

## What problem is the project solving?

The system treats long-term health as two interacting problems:

1. **Ageing** — changes in cells, tissues, organs and biological systems over time.
2. **Pathology** — disease, infection, inflammation, cancer, injury and other abnormalities that can occur at any age.

Both should be monitored simultaneously, while keeping observation, inference and intervention decisions separate.

```text
                         HUMAN ORGANISM
                                |
                +---------------+---------------+
                |                               |
             AGEING                          PATHOLOGY
                |                               |
        cellular changes                 disease processes
        tissue degeneration              inflammation
        molecular changes                infection
        functional decline               cancer
                |                               |
                +---------------+---------------+
                                |
                         BIOLOGICAL STATE
                                |
                 anomaly / trend / uncertainty
                                |
                       next measurement
                                |
                         state is updated
```

---

## Multimodal monitoring

Different biological layers require different measurement technologies. The architecture separates **acquisition, quality assessment, analysis and integration**.

Possible modalities include:

- MRI for structural measurements;
- microscopy for cellular and skin morphology;
- histopathology for tissue architecture;
- cell segmentation and single-cell analysis;
- RNA / transcriptomics;
- future proteomics and metabolomics;
- blood and laboratory measurements;
- physiological and wearable data;
- other specialised instruments as the project evolves.

```text
 MRI -----------+
 microscopy -----+
 histology ------+
 single-cell ----+----> modality-specific analysis
 RNA ------------+             |
 blood ----------+             v
 wearables ------+       biological features
                              |
                              v
                    quality / uncertainty
                              |
                              v
                     multimodal fusion
                              |
                              v
                      biological state
```

A new device should be addable without redesigning the whole system.

---

## Biological state instead of one health score

The project deliberately avoids reducing a person to a single value such as `biological_age = 52`.

Instead, the model is hierarchical:

```text
molecule -> cell -> tissue -> organ -> system -> organism
```

Observations should retain time, anatomy, modality, provenance, processing/model version and uncertainty where available.

The repository now contains foundations for hierarchical state, longitudinal organism history and trend analysis. These components are still research prototypes and are not a validated clinical representation of a human being.

---

## Current architecture

Stages 1–15 established the original biological monitoring foundation. Stages 16–24 extend it with multimodal integration, longitudinal modelling, intervention surveillance and validation primitives.

```text
core/
    common biological data model
    measurement / biomarker / anatomy / quality primitives

analysis/
    anomaly detection
    longitudinal trend analysis
    other modality-specific analysis components

segmentation/
    cell segmentation baseline

pipelines/
    cell analysis pipeline

organs/
    organ models and dependency graph
    signal propagation between organs

organism/
    organism-level state
    health-state aggregation
    digital biological twin foundation

longitudinal/
    earlier trajectory components

aging/
    biological clocks
    ageing profiles
    ageing trajectories

monitoring/
    longitudinal monitoring cycles
    anomaly -> risk -> investigation loop

intervention/
    intervention surveillance
    separate efficacy and safety tracking

validation/
    reproducible validation metrics
    subgroup evaluation

tests/
    unit tests for implemented components where available
```

The architecture is intentionally modular so future imaging, omics and physiological models can plug into the same biological-state representation.

---

## Development stages completed

### Stage 1 — Biological data core

Established common representations for subjects, timepoints, observations, measurements, biological states, biomarkers, anatomy and uncertainty.

### Stage 2 — First cell pipeline

Connected image/cell analysis to the common data model. The baseline pipeline can produce measurements such as cell count, density, area, compactness and spatial statistics.

### Stage 3 — Organ modelling

Introduced explicit organ-level state representation and organ dimensions.

### Stage 4 — Organ relationships

Added dependencies between organs, creating a graph representation of biological relationships.

### Stage 5 — Anomaly/risk foundation

Established prototype mechanisms used to represent abnormal signals and aggregate risk-related information.

### Stage 6 — Tissue/organ integration

Connected lower-level biological observations with higher-level organ state.

### Stage 7 — Biological ageing foundation

Introduced ageing-related scoring and biological-clock concepts.

### Stage 8 — Intervention analysis foundation

Established a research representation for evaluating intervention-related observations and effects. It is not a treatment recommendation engine.

### Stage 9 — Risk/pathology integration

Added prototype analysis components for pathology, risk and abnormality interpretation.

### Stage 10 — Organ-level signal propagation

Added `organs/propagation.py` to propagate an observed signal through the organ dependency graph while retaining the propagation path.

### Stage 11 — Whole-body organism model

Added `organism/organism_model.py` with `OrganismState` and `OrganismModel`. The model stores longitudinal organism states and supports comparison of successive biomarker observations.

### Stage 12 — Integrated health state

Added `organism/health_state.py` with `HealthState` and `HealthStateAggregator`, combining organ signals and organism-level anomaly flags into a transparent whole-body summary.

### Stage 13 — Longitudinal trajectories

Added `longitudinal/trajectory.py` and the public trajectory API. The system can calculate direction, change and slope for repeated biological measurements.

### Stage 14 — Ageing trajectories

Added `aging/aging_trajectory.py` so individual biological ageing dimensions can be tracked over time and their rate of change estimated.

### Stage 15 — Continuous monitoring loop

Added the monitoring layer that stores repeated monitoring cycles containing organism state, anomalies, risk information and investigation/next-step information.

### Stage 16 — Unified multimodal observation layer

Introduced a common representation for observations coming from different modalities, with explicit measurement provenance and quality metadata.

### Stage 17 — Measurement quality and uncertainty

Added quality-aware handling so unreliable observations can be excluded or represented as insufficient evidence rather than forcing a conclusion.

### Stage 18 — Multimodal fusion

Added quality-weighted fusion primitives for combining evidence while retaining modality provenance.

### Stage 19 — Hierarchical biological state

Added `core/hierarchy.py`, connecting organism, system, organ, tissue, cell-population, cell and site levels into a navigable hierarchy and allowing measurements to propagate through that hierarchy.

### Stage 20 — Digital Biological Twin foundation

Added `organism/digital_twin.py` with longitudinal `TwinSnapshot` objects and a persistent `DigitalBiologicalTwin` representation. This is a data-model foundation, not a complete predictive digital twin.

### Stage 21 — Advanced anomaly detection

Added `analysis/advanced_anomaly.py` for transparent anomaly scoring with quality thresholds, modality provenance and explicit `insufficient_evidence` handling.

### Stage 22 — Longitudinal biological change analysis

Added `analysis/longitudinal.py` for repeated measurements, trend direction, slope, baseline-to-latest change and quality-aware evidence filtering.

### Stage 23 — Intervention surveillance

Added `intervention/surveillance.py` and tests to track intervention observations while keeping efficacy and safety trajectories separate. This is a research monitoring primitive, not a treatment recommendation system.

### Stage 24 — Validation framework

Added `validation/framework.py` and tests for reproducible MAE, RMSE and bias calculations, quality filtering and subgroup evaluation. This establishes validation primitives; it is not clinical validation.

---

## Integrated architecture

The current direction can be represented as:

```text
                 MULTIMODAL OBSERVATIONS
                          |
                          v
                 QUALITY / UNCERTAINTY
                          |
                          v
                   MODALITY ANALYSIS
                          |
                          v
                   MULTIMODAL FUSION
                          |
                          v
              HIERARCHICAL BIOLOGICAL STATE
                          |
                          v
                 DIGITAL BIOLOGICAL TWIN
                          |
             +------------+------------+
             |                         |
             v                         v
       ANOMALY DETECTION       LONGITUDINAL ANALYSIS
             |                         |
             +------------+------------+
                          |
                          v
                  INTERVENTION SURVEILLANCE
                    /                 \
                   v                   v
               efficacy              safety
                          |
                          v
                    VALIDATION
                          |
                          v
                  updated state
                          |
                          +----> next measurement
```

The project is therefore moving from a collection of analysis modules toward a **closed-loop research architecture**. Integration and validation are now higher priorities than adding isolated scores.

---

## Biological ageing

Ageing should be represented by multiple dimensions rather than one universal clock.

Potential dimensions include:

```text
Cellular age
Tissue age
Immune age
Vascular age
Skeletal age
Neural age
Metabolic age
Molecular age
Functional age
```

For ageing research, **rate of change can be more informative than a single age estimate**. The repository contains transparent trend/slope primitives, but it does not contain a clinically validated biological-age clock.

A future ageing layer should distinguish at least:

```text
normal variation
      vs
measurement artefact
      vs
age-associated change
      vs
pathological change
      vs
intervention response
```

---

## Abnormality and disease detection

The intended system should detect both known and potentially unknown abnormalities:

- cellular abnormalities;
- tissue abnormalities;
- morphology changes;
- molecular abnormalities;
- pathology signals;
- longitudinal changes;
- disagreement between modalities;
- open-set or previously unseen patterns.

The system should be allowed to return **insufficient evidence** or **additional measurement required** instead of forcing an unjustified classification.

The current repository contains research prototypes and transparent scoring/aggregation components, not clinically validated diagnostic models.

---

## Digital Biological Twin

A major long-term objective is a **Digital Biological Twin**: an evolving computational representation of an individual's biological state.

```text
                    DIGITAL BIOLOGICAL TWIN
                              |
       +----------------------+----------------------+
       |                      |                      |
     organs                 tissues                cells
       |                      |                      |
   function                morphology             state
       |                      |                      |
       +----------------------+----------------------+
                              |
                         molecular state
                              |
                        ageing trajectories
                              |
                         disease/risk state
                              |
                         interventions
                              |
                         uncertainty
```

The current `organism/digital_twin.py` provides the **persistent snapshot/history foundation**. A complete predictive or mechanistic digital twin is not yet implemented.

---

## Intervention and rejuvenation research

A long-term research objective is to monitor interventions intended to preserve or restore biological function.

Partial cellular reprogramming involving **Yamanaka factors** is one example of a research direction that illustrates why efficacy and safety must be monitored separately. Potential cellular rejuvenation effects must be evaluated alongside risks such as loss of cell identity, abnormal proliferation and tumour formation.

The current intervention layer records efficacy and safety observations separately; it does not implement a rejuvenation therapy, select a therapy, or recommend treatment.

```text
                    INTERVENTION
                         |
          +--------------+--------------+
          |                             |
       efficacy                        safety
          |                             |
    functional effect          toxicity / adverse signal
          |                             |
          +--------------+--------------+
                         |
                    updated state
                         |
                  longitudinal follow-up
```

---

## Safety and decision philosophy

The system is being designed around several safety principles:

1. **Observation is not diagnosis.**
2. **A risk score is not a medical decision.**
3. **Uncertainty must be represented rather than hidden.**
4. **Conflicting measurements should trigger investigation, not arbitrary averaging.**
5. **Potential intervention benefit must be monitored separately from toxicity and safety.**
6. **Automated outputs require appropriate human and clinical oversight before clinical use.**
7. **Insufficient evidence is a valid system outcome.**

The long-term decision layer should prefer actions such as **measure again**, **request another modality**, **review by an expert**, or **insufficient evidence** when uncertainty is high.

---

## Validation roadmap

Stage 24 provides basic validation metrics, but that is only the beginning of scientific validation:

```text
unit tests
   ↓
integration tests
   ↓
benchmark datasets
   ↓
external validation
   ↓
longitudinal cohorts
   ↓
prospective studies
   ↓
clinical validation
   ↓
regulatory / safety assessment
```

Performance must eventually be evaluated separately for different modalities, populations, anatomical regions, diseases and measurement conditions. Reproducibility, calibration, data provenance and subgroup performance are essential.

A numerical metric on a retrospective dataset must not be presented as proof of clinical utility.

---

## Future roadmap — Stage 25+

The next development direction should prioritize integration and reliability:

### Stage 25 — Unified observation-to-twin pipeline

Connect the existing observation, quality, fusion, hierarchy and digital-twin layers into one typed end-to-end data flow.

### Stage 26 — Temporal anomaly and change-point detection

Distinguish isolated outliers from persistent changes, acceleration and regime shifts in longitudinal data.

### Stage 27 — Multimodal disagreement and measurement planning

Detect conflicts between modalities and produce transparent suggestions for which additional measurement could reduce uncertainty. This should remain a research planning layer, not autonomous clinical ordering.

### Stage 28 — Ageing versus pathology model

Build a research framework that separates normal variation, age-associated trajectories, pathology and intervention effects while preserving uncertainty.

### Stage 29 — Prospective validation infrastructure

Add dataset versioning, cohort definitions, reproducible experiments, calibration, subgroup reporting and longitudinal evaluation.

### Stage 30 — Research-grade decision and audit layer

Create an auditable layer that records evidence, model versions, uncertainty, decisions and human review before any future clinical translation.

---

## Important limitations

`testHP` is currently a **research prototype**. It should not be used to diagnose disease, prescribe treatment, determine biological age for medical purposes, or make autonomous clinical decisions.

Many concepts in the architecture remain future goals. In particular, a complete predictive digital biological twin, clinically validated ageing models, clinically validated multimodal fusion, validated intervention monitoring and clinical decision support are **not yet implemented**.

The 200-year lifespan objective is a long-term research vision, not a demonstrated outcome of the software.

---

## Project status

**Current stage: Stage 24 — validation framework implemented; early research prototype.**

Stages 1–24 establish a path from multimodal biological observations through quality assessment, fusion, hierarchical state, longitudinal modelling, anomaly detection, intervention surveillance and basic reproducible validation.

The immediate technical priorities are now **integration, correctness, testing, reproducibility and scientific validation**, rather than simply adding more scoring models.

The intended direction is:

```text
measure
  -> validate quality
  -> analyse
  -> integrate
  -> understand state
  -> detect change
  -> estimate risk
  -> monitor interventions separately
  -> validate outputs
  -> choose the next measurement
  -> update the model
  -> repeat
```

The ultimate goal is to build a platform that can continuously construct and update a **computational representation of human biological state**, enabling research into long-term health, ageing, disease prevention and biological rejuvenation.
